PPT-Clostridium Difficile Toolkit has been

updated Clostridium Difficile Prevention Primer is available at http wwwcdcgovhaipdfstoolkitsCDIPrimer22016pdf. (CDI). . Infections Toolkit. . Activity C: ELC Prevention Collaboratives. Draft - 12/23/09 --- Disclaimer: The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.. Clostridium . difficile. Infection (CDI). for Non-Clinical . Healthcare Workers. HAI Prevention Strategies Subcommittee. August 2011. These presentation slide sets were developed by the Prevention Strategies Subcommittee of the Arizona Healthcare-Associated Infection (HAI) Advisory Committee. Their works was guided by the best available evidence at the time this document was created. The objectives of the PSS are directed at providing access to additional resources for healthcare facilities, creating a repository of informational anc constructing a toolkit of strategies to assist facilities in preventing healthcare-associated infections.. Clostridium difficile. Infections. Dale N. Gerding, MD. Chair, National and Global Public Health Committee, Infectious Diseases Society of America. The comments and statements of the presenter are his own and those of the Infectious Diseases Society of America and do not officially represent the views or position of the United States Department of Veterans Affairs or Loyola University Chicago Stritch School of Medicine.. Clostridium . difficile. , CMV and enteric pathogens: . Case . studies. David G. . Binion. , MD. Bruce E. Sands, MD, MS. Case 2: Severe Pouch Inflammation. 3. 2 . yo. woman undergoing a 3 stage colectomy and J pouch reconstruction for refractory ulcerative colitis. Kevin W. Garey, PharmD. , MS, FASHP. Professor and Chair. Department . of Pharmacy Practice and Translational Research. Update on progress of city-wide stewardship projects. Focus on a better understanding of antimicrobial resistance in the Houston area. Kevin W. Garey, PharmD. , MS, FASHP. Professor and Chair. Department . of Pharmacy Practice and Translational Research. Update on progress of city-wide stewardship projects. Focus on a better understanding of antimicrobial resistance in the Houston area. Kevin W. Garey, PharmD. , MS, FASHP. Professor and Chair. Department . of Pharmacy Practice and Translational Research. Update on progress of city-wide stewardship projects. Focus on a better understanding of antimicrobial resistance in the Houston area. Clostridium difficile Infection (CDI) Guideline Update: Understanding the Data Behind the Recommendations Erik R. Dubberke, MD, MSPH Associate Professor of Medicine Washington University School of Medicine Understanding the Data Behind the Recommendations. Erik R. Dubberke, MD, MSPH. Associate Professor of Medicine. Washington University School of Medicine. Summary of Key Changes from 2010 Guidelines. Epidemiology. Welcome!. All lines are muted, so please ask your questions in chat. For technical issues, chat to the ‘Technical Support’ Panelist . Please actively participate in the poll that will pop up on the lower righthand side of your screen at the end of the presentation. Prior studies show that 3 - 26% of hospitalized patients are asymptomatically colonized with C. difficile . Available assays are not able to distinguish between C. difficile infection and coloniz Chapter 13: Updated:  Potential Food Safety Hazard  Control Measures  FDA Guideline  Growth  Heat Resistance  Analytical Procedures o Food sampling and preparation of sample homoge Jhung MA, Thompson AD, Killgore GE, Zukowski WE, Songer G, Warny M, et al. Toxinotype V Clostridium difficile in Humans and Food Animals. Emerg Infect Dis. 2008;14(7):1039-1045. https://doi.org/10.3201/eid1407.071641. Elsayed S, Zhang K. Human Infection Caused by Clostridium hathewayi. Emerg Infect Dis. 2004;10(11):1950-1952. https://doi.org/10.3201/eid1011.040006.